Delivery Order SPE2DR25D2014-SPE2DR26FA0H9
- Not listed
- The Defense Logistics Agency awarded a $28,123.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes. The contract, which is non-set-aside and competitively awarded, has an ultimate completion date of October 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a discrete purchase under a larger procurement vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $49,395.60 to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Tezspire 210 mg/1.91 ml syringes. This firm fixed-price delivery order, which carries no set-aside designation, is scheduled for completion by December 31, 2025, with performance occurring at the awardee's facility in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment of severe asthma, reflecting the breadth of...
- The Defense Logistics Agency awarded a $14,061.54 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL syringes on October 29, 2025, with a completion date of November 20, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $46.87K delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Tezspire 210 mg/1.91 ml syringes. This non-competitive, firm fixed-price delivery order is set to be completed by October 6, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99M...
- The Defense Logistics Agency awarded a $24,697.80 delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes. This firm fixed-price contract, with an ultimate completion date of December 29, 2025, represents a competitively awarded, non-set-aside procurement supporting federal medical supply requirements. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,469.78 firm fixed price delivery order to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Tezspire 210 mg/1.91 ml syringes. The contract, which carries an ultimate completion date of December 10, 2025, was competitively awarded with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Tezspire 210 mg/1.91 mL syringes with a ceiling value of $7,030.77. This is a firm fixed price delivery order with no set-aside designation, indicating the award was competitively procured. The contract is scheduled for ultimate completion by September 17, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $12,348.90 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL syringes on November 14, 2025, with completion expected by December 8, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract supports the procurement of this specialized pharmaceutical product for federal...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL syringes on September 9, 2025, with completion expected by September 30, 2025. This non-competitive, firm fixed-price delivery order represents a continuation of supply fulfillment under the company's existing indefinite delivery contract vehicle. The product will be delivered to the vendor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a $9.88K delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL syringes on December 11, 2025, with completion scheduled for January 5, 2026. This firm fixed-price delivery order represents a direct purchase under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The order was competitively awarded without set-aside designation and will be fulfilled...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FA0H9Delivery Order
The Defense Logistics Agency awarded a $12,348.90 delivery order to AmerisourceBergen Drug Corp on December 19, 2025, for the supply of Tezspire 210 mg/1.91 ml syringes. This is a firm fixed-price, competitively awarded contract with an ultimate completion date of January 13, 2026, with performance to be completed at the vendor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting the vendor's demonstrated capability to compete in open federal procurement. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. The Tezspire product supplied under this order is a specialized biologic medication used for moderate to severe eosinophilic asthma treatment, supporting the company's role in delivering specialty pharmaceutical products across the Department of Defense's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.3k | 12/18/25 |